Interestingly, mice depleted of CD4+ T cells also demonstrated earlier resistance development to BRAFi therapy indicating an essential contribution of CD4+ T cells to tumor regression caused by BRAFi treatment (figure 6A). The gene discussed is CD4; the disease is neoplasm.